Adaptimmune Reports Q4 Revenue $1.2M, Faces Profitability Challenges

Adaptimmune Therapeutics reported its Q4 and full-year 2024 performance, noting a product revenue of $1.2 million from its sarcoma drug, Tecelra, which has shown promising launch momentum with 10 patients apheresed in Q1 2025. Despite earning an EPS of -0.16, aligning with analyst expectations, the company is strategically focused on expanding its network of Authorized Treatment Centers (ATCs), aiming for around 30 by the end of 2025. Adaptimmune completed a corporate restructure in February 2025 to optimize costs and is assessing strategic options to maximize shareholder value as it targets profitability by 2027. The CEO, Adrian Rawcliffe, emphasized the company's commitment to commercial execution and the successful achievement of manufacturing and supply goals. The liquidity position at the end of 2024 stood at $152 million, crucial for sustaining operations in the capital-intensive biopharmaceutical landscape. The next product in the pipeline, lete-cel, is on track for a rolling BLA submission in late 2025.